Company Profile

The Need for Greater Cancer Technology Development:

Cancer is the leading cause of premature death in the U.S., Western Europe, Australia, and China. Few cancers are curable. For most tumor types, median survival rates have increased -- BUT overall survival rates have not increased. Life extension with therapy averages from 5 to 10 months. The cost of adjunct cancer therapy can be $120K to $650K.

The Response - ASOCs

Cancer cells can be reprogrammed to "behave" by altering expression of their genes. The challenge is to deliver cargo into cancer cells to alter gene expression. OncoArrestin created Antibody Substrate Oligonucleotide-Conjugate (ASOCs) to do this utilizing the Xyton Stealth Delivery™ (XSD™) System for final delivery of RNAi oligonucleotides into tumor cells.

OncoArrestin LLC:

OncoArrestin, LLC is a Delaware-registered company located in Gaithersburg, MD. It was set up as a therapeutics company to develop the delivery technologies originally invented and patented by OncoImmunin, Inc. The latter company, founded in 1994 in Maryland, first developed a cell-permeable fluorogenic protease substrate technology for studying apoptosis, cell-mediated cytotoxicity including antibody-dependent cellular cytotoxicity (ADCC) as well as additional applications.

Technology:

By modifying the design properties that made peptides of 18-20 amino acids cell permeable, delivery of oligonucleotides into cells and tissues was achieved. The result was the Xyton Stealth Delivery platform, a now patented method for the in vivo delivery of oligonucleotides. Combining knowledge and know-how from these inventions, we started OncoArrestin and are currently developing Antibody Substrate Oligonucleotide Conjugates (ASOCs) to create the next generation of drugs for immmunotherapy.